ASCO will grade drugs

Share this content:

The American Society of Clinical Oncology is taking notes. BioCentury reports that the professional society is grading cancer drugs based on benefit, toxicity and cost.

Chief Medical Officer Richard Schilsky told BioCentury that the scorecard is necessary because the price of a drug does not always reflect its impact.

Share this content:
Scroll down to see the next article